Angiogenic Switch in Patients With Colorectal Cancer
NCT02075086
Interventional
Phase 2
Unknown status
ANGIOSWITCH
A group of colorectal cancer (CRC) patients treated with chemotherapy and Bevacizumab (Bev) maintain the same sensitivity after progression to maintenance treatment because they remain dependent on VEGF angiogenic mediator, while other patients in whom there is an angiogenic switch (AS) become dependent on other angiogenic cytokines and become resistant to Bev chemotherapy combinations .
Jul 31,2011
All
18 Years
85 Years
18 Years
85 Years
100